Fagron Completes Acquisition of University Compounding Pharmacy (UCP)

Pharma Fusion Acquires Columbia Pharmacy

April 7, 2026

Healthcare Services

Pharma Fusion announced it has acquired Columbia Pharmacy, a Chicago-based specialty and 340B pharmacy provider. The deal is intended to expand Pharma Fusion’s clinical footprint and national specialty infrastructure, including care programs for complex, rare, and chronic conditions. Pharma Fusion says the acquisition will extend its 2026 revenues to over $150 million and add proprietary AI-driven health score and data infrastructure for patient support.

Fagron Completes Acquisition of University Compounding Pharmacy (UCP) in North America

January 12, 2026

Healthcare Services

Fagron has completed its acquisition of University Compounding Pharmacy (UCP), a 503A compounding pharmacy based in California and focused on health and wellness. The deal, announced in September 2025, strengthens Fagron’s U.S. footprint—particularly in California—and supports its strategy to build a nationwide platform spanning both 503A and 503B services.

Fagron Completes Acquisition of Purifarma

January 6, 2026

Healthcare Services

Fagron has announced the completion of its acquisition of Purifarma in Brazil, following CADE approval in October 2025. The company said the deal strengthens its scalable platform in essentials, with opportunities to improve the product mix, expand to industrial customers, and leverage purchasing advantages across Latin America.

Fagron Completes Acquisition of Purifarma in Brazil

January 6, 2026

Healthcare Services

Fagron announced the completion of its acquisition of Purifarma in Brazil following CADE competition clearance in October 2025. The deal strengthens Fagron’s scalable pharmaceutical compounding platform and supports its disciplined buy-and-build strategy, with an enterprise value of approximately R$250 million.

Eden Health Acquires Contigo Compounding

August 19, 2025

Healthcare Services

Eden Health has acquired Contigo Compounding, a licensed 503A compounding pharmacy, to integrate in-house sterile and non-sterile compounding capabilities into its personalized care platform. The acquisition gives Eden direct control of medication preparation and supply chain for faster adjustments, improved adherence, and next-day shipping for members.

Revelation Pharma Acquires Taylors Pharmacy and Key Compounding Pharmacy

July 9, 2024

Healthcare Services

Revelation Pharma, a national network of 503A and 503B compounding pharmacies, has acquired Taylors Pharmacy (Florida) and Key Compounding Pharmacy (Federal Way, Washington). The acquisitions expand Revelation's coast-to-coast footprint and bring both pharmacies into its compounding network as Revelation assumes full operations; the sellers are the founders/owners Allen Deaver and HeeJoo Park.